Illumina, Qiagen, Columbia University genomics news

Illumina is seeking to amend its counterclaim in a suit filed by the university in the U.S. District Court for the District of Delaware to add counterclaims for infringement by Intelligent Bio-Systems Inc. The patents in the suit, U.S. Patent Nos. 7,057,026; 7,785,796; and 8,158,346, cover labeled nucleotides. Illumina is also seeking to add Qiagen as a defendant because the company acquired Intelligent Bio-Systems "several weeks ago," according to the July 20 filling. Illumina said the infringing conduct is based on IBS' and Qiagen's platform for their MAX-Seq and MINI-20 DNA sequencers. The patents expire in December 2022. Illumina is seeking all available remedies, including injunctive relief (see BioCentury, July 2). ...